Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Takeda Aims at New Drug Development through Open Innovation
October 7, 2011
- Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
- Takeda US Unit Withdraw sNDA for Velcade
October 7, 2011
- Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
- Eli Lilly Receives Positive Opinion from CHMP for Alimta as Maintenance Therapy for NSCLC
October 7, 2011
- Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
- Ranbaxy Starts Selling Daiichi Sankyo Drugs in Italy
October 6, 2011
- Eli Lilly Japan Applies for Approval of Fast-Acting Zyprexa Intramuscular Inj.
October 6, 2011
- Nihon Chouzai Introduces Catalog Retailing at All Its Stores
October 6, 2011
- Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
- Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
- Rating Companies Downgrade Takeda following Acquisition of Nycomed
October 4, 2011
- Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
- Shionogi Announces International Industry-Academic Collaboration Program
October 4, 2011
- Taisho HD Listed on 1st Section of Tokyo Stock Exchange with Closing Price of ¥6,750 on 1st Day of Trading
October 4, 2011
- Eisai Sets Up Aricept Dept. to Boost Japan Marketing Efforts
October 3, 2011
- Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th
October 3, 2011
- Avastin Recommended as 1st Line Treatment for Advanced Ovarian Cancer in Europe: Roche
October 3, 2011
- GSK Is Able to Supply Cervarix for Vaccination at Subjects’ Own Expense
October 3, 2011
- Number of MRs in Japan Breaks 60,000 for 1st Time: MREAC
October 3, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…